NL-OMON41010
Withdrawn
Phase 4
Renal Sympathetic Denervation in patients with therapy-resistant Catecholamine Polymorphic Ventricular Tachycardia (CPVT) and Long QT Syndrome (LQTS) * RESIDENT Study - RESIDENT Study
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 20
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion Criteria
- •1\. Subjects who have provided written informed consent;
- •2\. Subjects who are \* 18 years of age;
- •3\. Subjects who in the last year have had at least 1 event related to therapy refractory CPVT or LQTS
- •4\. Subjects with a eGFR \* 45 ml/min per 1\.73m2;
- •5\. Subjects who are willing and able to comply with all study procedures. ;Anatomical Inclusion Criteria
- •1\. Subjects with or without an accessory renal artery who have a main renal artery diameter of \* 3\.5 mm and \* 7\.0 mm for each of their kidneys
- •2\. Subjects who have a main renal artery without significant stenosis (defined as \< 30%)
- •3\. Subjects who have a renal artery length of \* 15 mm.
Exclusion Criteria
- •1\. Subjects who are contraindicated for intravascular contrast material;
- •2\. Subjects who are contraindicated for anticoagulation medications (heparin, aspirin, Angiomax, etc.), analgesic medications (morphine, fentanyl, etc.), anxiolytic medications (alprazolam, lorazepam, diazepam, etc.) or other medications required for an interventional procedure;
- •3\. Subjects with known bleeding or hyper\-coagulation disorders;
- •4\. Subjects who have type 1 diabetes mellitus;
- •5\. Subjects who have experienced a myocardial infarction, unstable angina pectoris, uncompensated heart failure, or a cerebrovascular accident within six (6\) months prior to the screening visit, or have widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques;
- •6\. Subjects who have planned percutaneous vascular or surgical intervention for any reason within the next six (6\) months;
- •7\. Subjects who have hemodynamically significant valvular heart disease for which reduction of blood pressure would be considered hazardous;
- •8\. Subjects who have any serious medical condition, which in the opinion of the investigator, may adversely affect patient safety or the efficacy of the procedure in the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders);
- •9\. Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior to the procedure;
- •10\. Subjects who have a known, unresolved history of drug use or alcohol abuse/dependency;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Withdrawn
Phase 4
Renal Sympathetic Denervation after Renal Transplantation Study - IHypertension10057166NL-OMON37506eids Universitair Medisch Centrum10
Completed
Phase 3
Study of Renal Sympathetic Denervation with Radiofrequency Ablation Catheter for Resitant Essential HypertensioJPRN-UMIN000012020Kanazawa University Graduate School of Medical Science, Division of Environmental Sience Disease Control and Homeostasis6
Active, not recruiting
Not Applicable
/AEUCTR2012-001066-14-ESConsorci Mar Parc de salut de Barcelona ( Parc de Salut Mar)
Completed
Phase 2
Denervation of the renal sympathetic nerves in heart failure with normal LV ejection fraction.heartfailurehigh blood pressure1001928010057166NL-OMON39827niversitair Medisch Centrum Utrecht16
Completed
Not Applicable
Effect of renal denervation on Muscle Sympathetic Nerve Activity in patients with uncontrolled hypertensioNL-OMON41590niversitair Medisch Centrum Utrecht20